A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm

Study Identifier
GMA-US-NEU-0271
CT.gov Identifier
NCT02245958
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Movement Disorders - Other
  • Eye Care - Other
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years * Treatment with Xeomin® and BOTOX® for at least 2 years each.
    Exclusion Criteria:
    * Having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission * Previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm.

    Protocol Summary

    This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.

    Study Locations

    Location
    Status
    Location
    Colonia Roma Z.P., Mexico, 06700
    Status
    Not applicable
    Location
    Wakefield, United Kingdom, WF1 4DG
    Status
    Not applicable